In the validation group, univariate analysis showed that the following factors were statistically significant: BMI, histology, clinical stage, CVC history, hypertension, NLR, coagulation function indexs(D-dimer, ATTT, PT and Fbg levels), biochemical routine indexs(albumin, LDH and TG levels), Pro-BNP, tumor biomarkers(CEA, CA125 and Pro-GPR levels), molecular driver status(ROS1 rearrangement and PD-L1 high expression) and historic treatment regimens(chemotherapy, radiotherapy, and immunotherapy history)(P<0.05). The gene discussed is ALDH18A1; the disease is Hypertension.